搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
The American Journal of Managed Care
34 分钟
Role of MRAs in HFmrEF and HFpEF
Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) ...
Health Digest on MSN
2 天
The 3 Best Beverages To Take Ibuprofen With (And The 3 Worst)
There are certain beverages that may be advantageous to take alongside ibuprofen. However, there are also drinks that you ...
verywellhealth
4 天
Elbow Pain From Lifting: Steps to Relieve Pain
If you feel elbow pain during or after lifting weights or any heavy object, start using ice immediately. Take additional ...
verywellhealth
4 天
Allergic Reaction: Symptoms, First Aid, Prevention
An allergic reaction happens when your body attacks a foreign, and typically harmless, substance. Here’s how to tell if ...
Medscape
5 天
Triptans Trump Newer, More Expensive Meds for Acute Migraine
The comparative efficacy and tolerability of oral migraine medications suggest four triptans are superior to the newer, more ...
San Francisco Examiner
5 天
Dengue Cases Mount in Los Angeles
The Los Angeles area is seeing a troubling increase in local dengue fever cases, health officials warned Wednesday.
Targeted Oncology
6 天
Ribociclib-Based Therapy Extends Survival in HR+/HER2– Breast Cancer
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Monthly Prescribing Reference
6 天
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
Cure Today
6 天
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
oncnursingnews
6 天
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈